![]() ![]() i It offers an easy-to-implement solution that provides superior insights ii that empower clinicians to tailor a woman’s breast screening regimen and potentially identify cancers earlier. ProFound AI Risk uniquely combines a range of risk factors, including age, breast density and subtle mammographic features, offering superior performance in assessing short-term risk compared to traditional breast cancer risk models. Information about these products will be available in the virtual iCAD booth ( ) throughout the meeting. New data supporting ProFound AI™ will also be presented at the meeting. The Company unveiled the technology at the European Congress of Radiology (ECR) virtual meeting from July 15-19, 2020. ProFound AI Risk is the first and only clinical decision support tool that provides an accurate two-year, breast cancer risk estimation that is truly personalized for each woman, based only on a screening mammogram. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced ProFound AI™ Risk received a CE Mark in Europe. NASHUA, N.H., J(GLOBE NEWSWIRE) - iCAD, Inc. ICAD unveils new technology and clinical research at major medical conference First and only commercially available clinical decision support tool provides accurate two-year breast cancer risk estimation personalized for each woman ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |